Here's how you can reach us...
  • Tel:
  • Email:

Pharmacodynamic Evaluation for Nucleic Acid Drugs

Inquiry

CD Formulation has a professional pharmacodynamic evaluation team. With years of experience, we have developed a comprehensive pharmacodynamic research platform. This platform enables us to conduct cellular pharmacokinetic studies and in vivo pharmacodynamic studies in various disease models based on customer requirements. We aim to assist in understanding the mechanisms of pharmacodynamic effects and conducting clinical translational research.

Why Pharmacodynamic Evaluation of Nucleic Acid Drugs?

Pharmacodynamic evaluation is a crucial step in the process of developing new drugs. By comprehensively assessing the therapeutic effects, mechanism of action, efficacy-dosage relationship, and safety of a drug in in vitro cellular and in vivo animal models, the therapeutic potential of a drug can be confirmed, optimal dosing regimen can be established, safety can be evaluated, and a solid scientific foundation can be provided for the design and implementation of subsequent clinical trials. Nucleic acid pharmacodynamic evaluation can encompass the primary pharmacodynamic studies of anti-inflammatory immunity, anti-tumor, cardiovascular system, respiratory system, metabolic diseases, and other drugs. This helps meet the requirements of in vivo experiments, mechanism exploration, and molecular biology research at various research levels, thereby elucidating the efficacy and safety of new drugs.

Explore Our Nucleic Acid Drugs Pharmacodynamic Evaluation Services

CD Formulation offers a full range of drug discovery and pharmacodynamic evaluation services for nucleic acid drug discovery with a high level of technical expertise. We are committed to providing our clients with comprehensive services at competitive quality, lead times, and market prices to accelerate your scientific research. Customers can choose to combine our services according to their own needs.

In Vivo Activity Evaluation for Nucleic Acid Drugs

In vivo activity is the gold standard for evaluating a drug's biological activity and serves as the initial non-human validation of integrated activity. Assessing drug efficacy in vivo is crucial in new drug discovery and development, as it significantly contributes to identifying candidate molecules and screening clinical target indications. We also offer drug efficacy evaluation for assisted reproduction drugs to cater to various new drug development projects and provide customized services as needed.

Fig.1 Different disease models for in vivo activity evaluation of nucleic acid drugs.Fig.1 Different disease models.(CD Formulation)

In Vitro Activity Evaluation for Nucleic Acid Drugs

We also offer in vitro drug efficacy testing services for various types of drugs, such as nucleic acid and protein assays, cell autophagy assays, cell proliferation assays, apoptosis assays, cell motility assays, and other experiments or tests. A detailed list of testing items is provided in the table below.

Category Test Items
Nucleic Acid and Protein Assay
  • qPCR
  • WB
  • ELISA
  • RNA m6A Methylation
  • IP Assay
  • Co-IP Assay
Cellular Autophagy Assay
  • Electron Microscope Observation of Autophagosome Formation
  • GFP-LC3 Fusion Protein Tracing
Cell Proliferation Assay
  • ATP Concentration Measurement
  • Cell Proliferation-related Antigen Detection
  • CCK-8 Assay
  • Flow Cytometry
  • MTT Assay
Apoptosis Detection
  • Tunnel Staining
  • Apoptosis Detection
  • Caspase-3 Activity Assay
Cell Motility Assay
  • Tunnel Staining
  • Flow Assay for Apoptosis
  • Caspase-3 Activity Assay
Other Assays
  • Cell Surface Antigens
  • Mitochondrial Membrane Potential Assay
  • Angiogenesis Assay
  • Cell Adhesion Assay
  • Cellular Immunofluorescence Assay
  • Oxidative Stress Assay
  • Biochemical Assay
  • Calcium Ion Concentration Assay

Our Technology Platform for Nucleic Acid Drugs Pharmacodynamic Evaluation 

Fig.2 Pharmacodynamic evaluation platforms for nucleic acids.Fig.2 Platforms for nucleic acid pharmacodynamic evaluation.(CD Formulation)

Why Choose Us for Nucleic Acid Drugs Pharmacodynamic Evaluation?

  • Our experienced and professional team will help you choose the right model for preclinical drug efficacy studies.
  • Strict in vivo experimental controls are essential to guarantee genuine and dependable results.
  • Our in vivo efficacy screening and in vitro experimental analysis platform can provide you with one-stop efficacy evaluation services and accelerate the experimental process.
  • We provide our customers with comprehensive services at competitive market prices, helping you effectively save on experimental costs.

Publication Data

Technology: Pharmacodynamic evaluation of anticoagulants developed using RNA aptamer technology

Journal: Circulation

IF: 35.5

Published: 2006

Results:

The authors evaluated in healthy volunteers a novel anticoagulation system (REG1, Regado Biosciences, Inc.) that employs an oligonucleotide bound to the factor IXa protein (drug, RB006) and its complementary oligonucleotide antidote (RB007). In this first-in-human trial, the primary objective was to characterize their safety and pharmacodynamic response. The results of this experiment represent the first human trial of an RNA analog and its complementary oligonucleotide antidote for use as an anticoagulant system. These findings contribute to an emerging platform of selective, actively reversible anticoagulants for patients with thrombophilic diseases of the venous and arterial circulation.

Fig.3 Effects of RB006 on pharmacodynamics.Fig. 3 Pharmacodynamic effects of RB006 at 0 to 3 hours after RB006 administration. (Dyke C K, et al., 2006)

CD Formulation's specialized technical team has extensive experience in studying the efficacy of nucleic acid drugs, ensuring that your research projects run smoothly and efficiently while saving money and speeding up the drug discovery process. Contact us for a customized solution.

Reference

  1. Dyke C K, Steinhubl S R, Kleiman N S, et al. First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation. 2006, 114(23): 2490-2497.
How It Works
STEP 2
We'll email you to provide your quote and confirm order details if applicable.
STEP 3
Execute the project with real-time communication, and deliver the final report promptly.
Related Services

At CD Formulation, we understand the unique challenges and opportunities associated with nucleic acid formulation development. Our team of experts is dedicated to providing tailored solutions...

Learn More

  • Tel:
  • Email:

Stay up to date with our latest releases of new research and promotions.

Copyright © CD Formulation. All Rights Reserved.   Privacy Policy  Cookie Policy